EU Clinical Trial 2018-003615-22

Efficacy and safety of twice-daily application of delgocitinib cream 20 mg/g for 6 weeks in subjects with active discoid lupus erythematosus. A phase 2a exploratory, randomised, double-blind, vehicle-controlled, within-subject, multi-centre trial.  May 28, 2019

Main objective of the trial: To investigate the efficacy of delgocitinib cream 20 mg/g twice daily on active DLE target lesions.

Parties

Sponsors
Countries
US
Keywords
Delgocitinib Delgocitinib cream Discoid lupus erythematosus LEO 124249

JSON preview

Similar records

Title

Source:  EMA Last updated:  Jun 5, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.